Tonix Pharmaceuticals raises up to $144M in registered direct offering

Tonix Pharmaceuticals Holding Corp.

Upfront $30M from sale of ~54M shares/pre-funded warrants at $0.555/share; up to $144M total with warrant exercise.
Series C warrants (2-yr term, $0.555 strike) and Series D warrants (5-yr term, $0.85 strike) exercisable only after shareholder approval.
Proceeds for NDA preparation for TNX-102 SL in fibromyalgia and working capital; closing expected Dec 22, 2023.
A.G.P./Alliance Global Partners placement agent; 45-day lock-up for insiders; 90-day restriction on future equity issuance.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Tonix Pharmaceuticals Holding Corp. entered into Purchase Agreement with certain institutional investors valued at up to approximately $144 million (effective 2023-12-20).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional investors
Value: up to approximately $144 million
Effective: 2023-12-20

Exact text from the filing

On December 20, 2023, Tonix Pharmaceuticals Holding Corp. (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (collectively, the “Purchasers”).

View on SEC.gov

273 material agreements filed in the last 30 days. Browse all material agreements →

Tonix Pharmaceuticals Holding Corp. filing history →

Source: SEC EDGAR

accession 0001999371-23-001135

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.